Controlling Severe Asthma through Advanced
Diagnosis and Treatment Strategies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals
practicing in managed care environments.

This educational activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Teva Pharmaceuticals

There is no cure for asthma, but it is possible to manage the disease successfully through a number of behavioral changes and therapies. Pharmacologic management can include using inhaled corticosteroids (ICS), long-acting beta-2 agonists, theophylline, and leukotriene modifiers. And while these are helping, several new therapies, such as anti-immunoglobulin E and anti-IL- antibodies, are aiming to control and treat asthma, which could improve the lives of patients with uncontrolled persistent asthma. The National Asthma Education and Prevention Program (NAEPP) and the Expert Panel Report 3 (EPR-3) emphasizes the assessment process from initial diagnosis to long-term management and the creation of a personalized treatment plan as the key components to patient adherence. The guidelines also state that healthcare professionals should take an initial assessment to determine the severity of asthma and to initiate treatment, and then at each follow-up visit, an additional assessment should be performed detailing information of symptom characteristics and information on patient treatment adherence, including all medications and behavioral modifications. Based upon these follow-up assessments, a written action plan should be developed by the physician and patient in order to create an individualized treatment regimen.

Upon Completion of this activity, participants will be able to:

  • Identify the safety and efficacy data for emerging therapies for severe asthma

  • Explore national and global treatment guidelines and recommendations, including the NAEPP and EPR-3, to control symptoms, reduce exacerbations, and improve the quality of life of severe asthma patients

  • Assess the potential implications of new clinical data on patient selection, diagnosis and treatment options

  • Discuss effective treatment plans to achieve and maintain control for patients with severe asthma whose symptoms are poorly controlled due to nonadherence

  • Analyze the emerging role for biomarkers and biologics in severe asthma pathophysiology and symptom management

Faculty: James F. Donohue, MD
Professor of Medicine
University of North Carolina School of Medicine
Division of Pulmonary Diseases
Division of Critical Care Medicine


Dr. Donohue serves on advisory boards/panels for AstraZeneca, DMC and Gilead and serves as a consultant to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Sunovion. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.  Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue